Rachel C Jankowitz
Overview
Explore the profile of Rachel C Jankowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Han M, Salamat A, Zhu L, Zhang H, Clark B, Dabbs D, et al.
Mod Pathol
. 2023 Jul;
36(8):100267.
PMID: 37453277
No abstract available.
12.
Gradishar W, Moran M, Abraham J, Abramson V, Aft R, Agnese D, et al.
J Natl Compr Canc Netw
. 2023 Jun;
21(6):594-608.
PMID: 37308117
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly....
13.
Gradishar W, Moran M, Abraham J, Aft R, Agnese D, Allison K, et al.
J Natl Compr Canc Netw
. 2022 Jun;
20(6):691-722.
PMID: 35714673
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients...
14.
Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley D, Isakoff S, et al.
NPJ Breast Cancer
. 2022 Feb;
8(1):18.
PMID: 35173164
The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic...
15.
Gradishar W, Moran M, Abraham J, Aft R, Agnese D, Allison K, et al.
J Natl Compr Canc Netw
. 2021 Nov;
19(5):484-493.
PMID: 34794122
The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast...
16.
Hoffman D, Santos P, Goldbach M, Keele L, Taunk N, Bogen H, et al.
Ann Surg Oncol
. 2021 Jul;
28(13):8789-8801.
PMID: 34269937
Introduction: National guidelines specify against immediate breast reconstruction (IBR) among inflammatory breast cancer (IBC) patients. However, limited data exist regarding this practice. We report practice patterns and oncologic outcomes among...
17.
Ruddy K, Zheng Y, Tayob N, Hu J, Dang C, Yardley D, et al.
Breast Cancer Res Treat
. 2021 Jun;
189(1):103-110.
PMID: 34120223
Purpose: Chemotherapy-related amenorrhea (CRA) is a surrogate for ovarian toxicity and associated risk of infertility and premature menopause. Here, we compare CRA rate with paclitaxel (T)-trastuzumab (H) to that with...
18.
Tolaney S, Tayob N, Dang C, Yardley D, Isakoff S, Valero V, et al.
J Clin Oncol
. 2021 Jun;
39(21):2375-2385.
PMID: 34077270
Purpose: The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS)...
19.
Hawrot K, Shulman L, Bleiweiss I, Wilkie E, Frosch Z, Jankowitz R, et al.
JCO Oncol Pract
. 2021 Mar;
17(9):534-540.
PMID: 33710914
Purpose: The COVID-19 pandemic has posed significant pressures on healthcare systems, raising concern that related care delays will result in excess cancer-related deaths. Because data regarding the impact on patients...
20.
Sreekumar S, Levine K, Sikora M, Chen J, Tasdemir N, Carter D, et al.
Endocrinology
. 2020 Jul;
161(9).
PMID: 32609836
Invasive lobular breast carcinoma (ILC) accounts for 10% to 15% of breast cancers diagnosed annually. Evidence suggests that some aspects of endocrine treatment response might differ between invasive ductal carcinoma...